SEARCH

SEARCH BY CITATION

References

  • 1
    Urabe K, Nakayama J, Hori Y. Mixed epidermal and dermal hypermelanoses. In: Norlund JJ, Boissy RE, Hearing VJ, King RA, Ortonne JP. The Pigmentary System: Physiology and Pathophysiology. New York: Oxford University Press; 1998. pp. 909911.
  • 2
    Cullen MK. Genetic epidermal syndromes: disorders characterized by lentigines. In: Norlund JJ, Boissy RE, Hearing VJ, King RA, Ortonne JP. The Pigmentary System: Physiology and Pathophysiology. New York: Oxford University Press; 1998. pp. 760766.
  • 3
    Ortonne JP, Nordlund JJ. Mechanisms that cause abnormal skin color. In: Norlund JJ, Boissy RE, Hearing VJ, King RA, Ortonne JP. The Pigmentary System: Physiology and Pathophysiology. New York: Oxford University Press; 1998. pp. 489502.
  • 4
    Im S, Kim J, On WY, Kang WH. Increased expression of α-melanocyte-stimulating-hormone in the lesional skin of melasma. Br J Dermatol 2002;146: 165167.
  • 5
    Kang WH, Yoon KH, Lee ES, Kim J, Lee KB, Yim H, Sohn S, Im S. Melasma: histopathological characteristics in 56 Korean patients. Br J Dermatol 2002;146: 228237.
  • 6
    Yasumoto K, Yokoyama K, Takahashi K et al. Functional analysis of microphtalmia-associated transcription factor in pigment cell-specific transcription of the human tyrosinase damily genes. J Biol Chem 1997;272: 503509.
  • 7
    Tachibana M. MITF: a stream flowing for pigment cells. Pigment Cell Res 2000;13: 230240.
  • 8
    Fang D, Tsuji Y, Setaluri V. Selective donw-regulation of tyrosinase family gene TYRP1 by inhibition of the activity of melanocyte transcription factor, MITF. Nucl Acids Res 2002;30: 30963106.
  • 9
    Watabe H, Soma Y, Ito M, Kawa Y, Mizoguchi M. All-trans-retinoic acid induces differentatiation and apoptosis of murine melanocyte precursors with induction of the microphtalmia-associated transcription factor. J Inv Dermatol 2002;118: 3542.
  • 10
    Yoshimura K, Tsukamoto K, Okazaki M, Virador VM, Lei TC, Suzuki Y, Uchida G, Kitano Y, Harii K. Effects of all-trans retinoic acid on melanogenesis in pigmented skin equivalents and monolayer culture of melanocytes. J Dermatol Sci 2001;27: 68s75s.
  • 11
    Romero C, Aberdam E, Larnier C, Ortonne JP. Retinoic acid as modulator of UVB-induced melanocyte differentiation. J Cell Sci 1994;107: 10951103.
  • 12
    Talwar HS, Griffiths EM, Fisher GJ, Russman A, Krach K, Benrazavi S, Voorhees JJ. Differential regulation of tyrosinase activity in skin of white and black individuals in vivo by topical retinoic acid. J Invest Dermatol 1993;100: 800805.
  • 13
    Rafal KS, Griffiths EM, Ditre CM, Finkel LJ, Hamilton TA, Ellis CN, Voorhees JJ. Topical tretinoin (retinoic acid) treatment for liver spot associted with photodamage. N Engl J Med 1992;326: 386374.
  • 14
    Bulengo-Ransby SM, Griffiths EM, Kimbrough-Green CK, Finkel LJ, Hamilton TA, Ellis CN, Voorhees JJ. Topical tretinoin (reinoic acid) therapy for hyperpigmented lesions caused by inflammation of the skin in black patients. N Engl J Med 1993;328: 14381443.
  • 15
    Kim DS, Kim SY, Moon SJ, Chung JH, Kim KH, Cho KH, Park KC. Ceramide inhibits cell proliferation trough Akt/PKB inactivation and decreases melanin synthesis in Mel-Ab Cells. Pigment Cell Res 2001;14: 110115.
  • 16
    Kim DS, Kim SY, Chung JH, Kim KH, Eun HC, Park KC. Delayed ERK activation by ceramide reduces melanin synthesis in human melanocytes. Cell Signal 2002;14: 779785.
  • 17
    Negriou G, Branza-Nichita N, Petrescu AJ, Dwek RA, Petrescu SM. Protein specific N-glycosylation of tyrosinase and tyrosinase-related protein-1 in B16 mouse melanoma cells. Biochem J 1999;344: 659665.
  • 18
    Imokawa G, Mishima Y. Functional analysis of tyrosinase isozymes od cultured malignant melanoma cells during the recovery period following interrupted melanogenesis induced by glycosilation inhibitors. J Invest Dermatol 1984;83: 196201.
  • 19
    Mishima Y, Imokawa G. Selective aberration and pigment loss in melanosomes of malignant melanoma cells in vitro by glycosilation inhibitors: premelanosomes as glycoprotein. J Invest Dermatol 1983;81: 106114.
  • 20
    Franchi J. Depigmenting effects of calcium d-pantetheine-S-sulfonate on human melanocytes. Pigment Cell Res 2000;13: 165171.
  • 21
    Passi S, Nazzaro-Porro M. Molecular basis of substrate and inhibitory specificity of tyrosinase: phenolic compounds. Br J Dermatol 1981;104: 659665.
  • 22
    Menter JM, Etemadi AA, Chapman W, Hollins TD, Willis I. In vivo depigmentation by hydroxybenzene derivatives. Melanoma Res 1993;6: 443449.
  • 23
    Perez-Bernal A, Munoz-Perez MA, Camacho F. Management of facial hyperpigmentation. Am J Clin Dermatol 2000;1: 261268.
  • 24
    Fisher AA. The safety of bleaching creams containing hyroquinone. Cutis 1998;61: 303304.
  • 25
    Sanchez JL, Vazquez M. A hydroquinone solution in the treatment of melasma. Int J Dermatol 1982;21: 5558.
  • 26
    Kauh YC, Zachian TF. Melasma. Adv Exp Med Biol 1999;455: 191499.
  • 27
    Kang WH, Chun SC, Lee S. Intermittent therapy for melasma in Asian patients with combined topical agents (retinoic, hydroquinone and hydrocortisone): clinical and histological studies. J Dermatol 1998;25: 587589.
  • 28
    Guevara IL, Pandya AG. Melasma treated with hydroquinone, tretinoin and a fluorinated steroid. Int J Dermatol 2001;40: 212215.
  • 29
    Smith CJ, O'Hare KB, Alle JC. Selective cytotoxicity of hydroquinone for melanocyte-derived cells is mediated by tyrosinase activity but independent of melanin content. Pigment Cell Res 1988;1: 386389.
  • 30
    Curto EV, Kwong C, Hermersdorfer H, Glatt H, Santis C, Virador V, Hearing VJ Jr, Dooley TP. Inhibitors of mammalian melanocyte tyrosinase: in vitro comparisons of alkyl esters of gentisic acid with other putative inhibitors. Biochem Pharmacol 1999;57: 663672.
  • 31
    Palumbo A, D'Ischia M, Misuraca G, Prota G. Mechanism of inhibition of melanogenesis by hydroquinone. Biochim Biophys Acta 1991;23: 8590.
  • 32
    Bolognia JL, Sodi SA, Obser MP, Pawelek JM. Enhancement of the depigmenting effect of hydroquinone by cystamine and buthionine sulfoxime. Br J Dermatol 1995;133: 349357.
  • 33
    Prota G. Melanins and melanogenesis. New York: Academic Press: 1992. pp. 1290.
  • 34
    Penney KB, Smith CJ, Allen JC. Depigmenting action of hydroquinone depends on disruption of fundamental cell processes. J Invest Dermatol 1984;82: 308310.
  • 35
    De Caprio AP. The toxicology of hydroquinone-relevance to occupational and environmental exposure. Crit Rev Toxicol 1999;29: 283330.
  • 36
    Njoo MD, Westerhof W, Bos JD, Bossuyt PM. The development of guideline for the treatment of vitiligo. Arch Dermatol 1999;135: 15141521.
  • 37
    Fenoll LG, Rodriguez-Lopez JN, Varon R, Garcia-Ruiz PA, Garcia-Canovas F, Tudela J. Action mechanism of tyrosinase on meta-and para-hydroxylated monophenols. Biol Chem 2000;38: 313320.
  • 38
    Fleicher AB, Schwartzel EH, Colby SI, Altman DJ. The combination of 2% 4-hydroxyanisole (Mequinol) and 0.01% tretinoin is effective in improving the appearance of solar lentigines and related hyperpigmented lesions in two phase double-blind multicenter clinical studies. J Am Acad Dermatol 2000;42: 459467.
  • 39
    Espin JC, Varon R, Tudela J, Garcia-Canovas F. Kinetic study of the oxidation of 4-hydroxyanisole catalized by tyrosinase. Biochem Mol Biol Int 1997;41: 12561276.
  • 40
    Rodriguez-Vicente J, Vicente-Ortega V, Canteras-Jordana M, Calderon-Rubiales F. Relationship between 4-hydroxyanisole and dopa oxidase activity for three melanoma cell lines. Melanoma Res 1997;7: 373381.
  • 41
    Yang F, Boissy RE. Effects of 4-tertiary butylphenol on the tyrosinase activity in human melanocytes. Pigment Cell Res 1999;12: 237245.
  • 42
    Riley PA, Cooksey CJ, Johnson CI, Land EJ, Latter AM, Ramsden CA. Melanogenesis-targeted anti-melanoma pro-drug development: effect of side-chain variations on the cytotoxicity of tyrosinase-generated ortho-quinones in a model screening system. Eur J Cancer 1997;33: 135143.
  • 43
    Thomas DP, Kishi H, Cao H, Ota M, Yamashita T, Singh S, Jimbow K. Selective incorporation and specific cytocidal wffwcts as the cellular basis for the antimelanoma action of sulphur containing tyrosine analogs. J Invest Dermatol 1999;113: 928934.
  • 44
    Gili A, Thomas PD, Ota M, Jimbow K. Comparison of in vitro cytotoxicity of N-acetyl and N-propionyl derivatives of phenolic thioether amines in melanoma and neuroblastoma cells and the relationship to tyrosinase and tyrosine hydroxylase enzyme activity. Melanoma Res 2000;10: 915.
  • 45
    Jimbow M, Marusyk H, Jimbow K. The in vivo melanocytoxicity and depigmenting potency of N-2,4-acetoxyphenyl thioethyl acetamide in the skin and hair. Br J Dermatol 1995;133: 526536.
  • 46
    Thorneby-Andersson K, Olov S, Hansson C. Tyrosinase-mediated formation of a reactive quinone from the depigmenting agents, 4-tert-butylphenol and 4-tert-butylcatechol. Pigment Cell Res 2000;13: 3338.
  • 47
    Naish-Byfield S, Riley PA. Tyrosinase kinetics. failure of acceleration in oxidation of ring-blocked monohydric phenol substrate. Pigment Cell Res 1998;11: 9497.
  • 48
    Sugai T. Clinical effects of arbutin in patients with chloasma (in Japanese). Hifu (Skin Res) 1992;34: 522529.
  • 49
    Maeda K, Fukuda M. Arbutin: mechanism of its depigmenting action in human melanocyte culture. J Pharmacol Exp Ter 1996;276: 765769.
  • 50
    Chakraborty AK, Funasaka Y, Komoto M, Ichihashi M. Effect of arbutin on melanogenic protiens in human melanocytes. Pigment Cell Res 1998;11: 206212.
  • 51
    Bolognia JL, Sodi SA, Pawelek JM. Two separate pathways in the regulation of pigmentation. J Invest Dermatol 1991;96: 632.
  • 52
    Cameli N, Marmo W, Gaeta A, Calderini G, Picardo M. Evaulation of clinically efficacy of a misture of depigmenting agents. Pigment Cell Res 2001;14: 406.
  • 53
    Battaini G, Monzani E, Casella L, Santagostini L, Pagliarin R. Inhibition of the catecholase activity of biomimetic dinuclear copper complexes by kojic acid. J Biol Inorg Chem 2000;5: 262268.
  • 54
    Kahn V. Effect of kojic acid on the oxidation of dl-DOPA, norepinephrine, and dopamine by mushroom tyrosinase. Pigment Cell Res 1995;8: 234240.
  • 55
    Moon KY, Ahn KS, Lee J, Kim YS. Kojic acid, a potential inhibitor of NF-kappa B activation intransfectant human HaCaT and SCC13 cells. Arch Pram Res 2001;24: 307311.
  • 56
    Lim JT. Treatment of melasma using kojig acid in a gel containing hydroquinone and glycolic acid. Dermatol Surg 1999;25: 282284.
  • 57
    Dooley TP, Gadwood RC, Kilgore K, Thomasco LM. Development of an in vitro primary screen for skin depigmentation and antimelanoma agents. Skin Pharmacol 1994;7: 188200.
  • 58
    Bocchietto E, Pecis L, D'Abrosca F, Losio N, Picardo M. In vitro testing of innovative depigmenting and low toxicity topic compositions. Pigment Cell Res 2001;14: 405.
  • 59
    Piao LZ, Patk HR, Park YK, Lee SK, Park JH, Park MK. Mushroom tyrosinase inhibition activity of some chromones. Chem Pherm Bull 2002;50: 309311.
  • 60
    Jones K, Hughes J, Hong M, Jia Q, Orndorff S. Modulation of melanogenesis by aloesin: a competitive inhibitor of tyrosinase. Pigment Cell Res 2002;15: 335340.
  • 61
    Jin YH, Lee SJ, Chung MH et al. Aloesin and arbutin inhibit tyrosinase activity in a synergistic manner via a different action mechanism. Arch Pharm Res 1999;22: 232236.
  • 62
    Choi S, Park YI, Lee SK, Kim JE, Chung MH. Aloesin inhibits hyperpigmentation induced by UV radiation. Exp Dermatol 2002;27: 513515.
  • 63
    Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997;275: 218220.
  • 64
    Subbaramaiah K, Chung WJ, Michaluart P, Telang N, Tanabe T, Inoue H, Jang M, Pezzuto JM, Dannenberg AJ. Resveratrol inhibits cycloxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem 1998;273: 2187521882.
  • 65
    Bernard P, Berthon JY. Resveratrol: an original mechanism on tyrosinase inhibition. Int J Cosmetic Sci 2000;22: 219226.
  • 66
    Kim YM, Yun J, Lee CK, Lee H, Min KR, Kim Y. Oxyresveratrol and hydroxystilbene compounds, inhibitory effect on tyrosinase and mechanism of action. J Biol Chem 2002;277: 1634016344.
  • 67
    Shimogaki H, Tanaka Y, Tamai H, Masuda M. In vitro and in vivo evaluation of ellagic acid on melanogenesis inhibition. Int J Cosmetic Sci 2000;22: 291303.
  • 68
    Lemic-Stoicevic L, Nias AH, Breathnach AS. Effect of azelaic acid on melanoma cell in culture. Exp Dermatol 1995;4: 7981.
  • 69
    Nazzaro-Porro M. Azelaic acid. J Am Acad Dermatol 1987;17: 10331041.
  • 70
    Nazzaro-Porro M, Passi S, Zina G, Breathnach AS. Then year's experience of treating lentigo maligna with topical azelaic acid. Acta Derm Venereol (Stockh). 1989;143 (Suppl.):4957.
  • 71
    Sarkar R, Bhalla M, Kanwar AJ. A comparative study of 20% azelaic acid cream monotherapy versus a sequential therapy in the treatment of melasma in dark-skinned patients. Dermatology 2002;205: 249254.
  • 72
    Nappi AJ, Vass E. Hydrogen peroxide generation associated with the oxidation of the eumelanin precursors 5,6-dihydroxyindole and 5,6-dihydroxy-2-carboxylic acid. Melanoma Res 1996;6: 341349.
  • 73
    D'Ischia M, Napolitano A, Prota G. Peroxidase as an alternative to tyrosinase in the oxidative polymerization of 5,6-dihydroxyindoles to melanin(s). Biochim Biophys Acta 1991;1073: 423430.
  • 74
    Meier B, Radeke HH, Selle S, Younes M, Sies H, Resch K, Habermehl GG. Human fibroblasts release reactive oxygen species in response to interleukin-1 or tumour necrosis factor-α. Biochem J 1989;263: 539545.
  • 75
    Thannickal VJ, Fanburg BL. Activation of an H2O2-generating NADH oxidase in human lung fibroblasyts by transforming growth factor-β1. J Biol Chem 1995;270: 3033430338.
  • 76
    Lo YYC, Wong JMS, Cruz TF. Reactive oxygen species mediate cytokine activation of c-jun NH2-terminal kinases. J Biol Chem 1996;271: 1570315707.
  • 77
    Jimenez-Cervantes C, Martinez-Esparza M, Perez C, Daum N, Solano F. Garcia-Borron JC. Inhibition of melanogenesis in response to oxidative stress: transient downregulation of melanocyte differentiation markers and possible involvement of microphtalmia transcription factor. J Cell Sci 2001;14: 23352344.
  • 78
    Kasraee B. Peroxidase-mediated mechanisms are involved in the melanocytotoxic and melanogenesis-inhibiting effects of chemical agents. Dermatology 2002;205: 329339.
  • 79
    Bandyopadhyay U, Biswas K, Bandyopadhyay D, Ganguly CK, Banerjeen RK. Dexamethasone makes the gastric mucosa susceptible to ulceration by inhibiting prostaglandin synthetase and peroxidase-two important gastroprotective enzymes. Mol Cell Biochem 1999;202: 3136.
  • 80
    Rogozhin VV, Vercoturov VV. Effect of antioxidants (digoxin, quercetin, and ascorbic acid) on catalytic properties of horseradish peroxidase. Biochemistry 1998;63: 657661.
  • 81
    Kasraee K. Depigmentation of brown guinea pig skin by topical application of methimazole. J Invest Dermatol 2002;118: 205207.
  • 82
    Karg E, Odh G, Wittbjer A, Rosengren E, Rorsman H. Hydrogen peroxide as inducer of elevated tyrosinase level in melanoma cells. J Invest Dermatol 1993;100: 209s213s.
  • 83
    Gukasyan GS. Study of the kinetics of oxidation of monophenols by tyrosinase. The effect of reducers. Biochemistry (Mosc) 2002;67: 277280.
  • 84
    Ros JR, Rodriguez-Lopes JN, Garcia-Canovas F. Effect of l-ascorbic acid on the monophelase activity of tyrosinase. Biochem J 1993;295: 309312.
  • 85
    Kameyama K, Sakai C, Kondoh S, Yonemoto K, Nishiyama S, Tagawa M, Murata T, Ohnuma T, Quigley J, Dorsky A, Bucks D, Blanock K. Inhibitory effect magnesium l-ascorbyl-2-phosphate (VC-PMG) on melanogenesis in vitro and in vivo. J Am Acad Dermatol 1996;34: 2933.
  • 86
    Shimizu K, Kondo R, Sakai K, Takeda N, Nagahata T, Oniki T. Novel vitamin E derivative with 4-substituited resorcinol moiety has both antioxidant and tyrosinase inhibitory properties. Lipids 2001;36: 13211326.
  • 87
    Ichihashi M, Funasaka Y, Ohashi A, Chakraborty A, Ahmed NU, Ueda M, Osaka T. The inhibitory effect of DL-alpha-tocopheryl ferulate in lecithin on melanogenesis. Anticancer Res 1999;19: 37693774.
  • 88
    Ochiai Y, Okano Y, Funasaka Y, Ichihashi M. Effects of α-Toc on In Vitro Aged Melanocytes. The 52nd Annual Meeting of the Central division of Japanese Dermatological Association 2001, Tokyo. p. 119.
  • 89
    Marmol VD, Solano F, Sels A, Huez G, Libert A, Lejeune F, Ghanem G. Glutathione depletion increases tyrosinase activity in human melanoma cells. J Invest Dermatol 1993;101: 871874.
  • 90
    Quevedo Jr WC, Holstein TJ, Dyckman J, Mcdonald CJ, Isaacson EL. Inhibition of tunning response and immunosuppression by topical application of Vitamin C and vitamin E to the skin of hairless (hr/hr) mice. Pigment Cell Res 2000;13: 8998.
  • 91
    Nishiyama T, Ohnishi J, Hashiguchi Y. Fused heterocyclic antioxidants. antioxidative activities of hydrocumarins in a homogeneous solution. Biosci Biotechnol Biochem 2001;65: 11271133.
  • 92
    Yamamura T, Onishi J, Nishiyama T. Antimelanogenic activity of hydrocumarins in cultured normal human melanocytes by stimulating intracellular glutathione synthesis. Arch Dermatol Res 2002;294: 349354.
  • 93
    Packer L, Witt H, Tritscheler H. Lipoic acid as a biological antioxidant. Free Rad Biol Med 1995;19: 227250.
  • 94
    Saliou C, Kitazawa M, McLaughlin L, Yang JP, Lodge JK, Tetsuka T, Iwasaki K, Cillard J, Okamoto T, Packer L. Antioxidants modulate acute solar ultraviolet radiation-induced NF-Kappa-B activation in a human keratinocyte cell line. Free Rad Biol Med 1999;26: 174183.
  • 95
    Ando H, Ryu A, Hashimoto A, Oka M, Ichashi M. Linoleic and α-linoleic acid lightens ultraviolet-induced hyperpigmentation of the skin. Arch Dermatol Res 1998;290: 375381.
  • 96
    Halaban E, Cheng E, Zhang Y, Moellmann D, Hanlon D, Michalak M, Setaluri V, Hebert DN. Aberrant retention of tyrosinase in the endoplasmic reticulum mediates accelerated degradation of the enzyme and contributes to the dedifferentiated phenotype of amelanotic melanoma cells. Proc Natl Acad Sci USA 1997;94: 62106215.
  • 97
    Ando H, Funasaka Y, Oka M, Ohashi A, Furumura M, Matsunaga J, Matsunaga N, Hearing VJ, Ichihashi M. Possible involvement of proteolytic degradation of tyrosinase in the regulatory effect of fatty acids on melanogenesis. J Lipid Res 1999;40: 13121316.
  • 98
    Seiberg M. Keratinocyte-melanocyte interaction during melanosome transfer. Pigment Cell Res 2001;14: 236242.
  • 99
    Minwalla L, Zhao Y, Cornelius J, Babcock GF, Wickett RR, Le Poole IC, Boissy RE. Inhibition of melanosome transfer from melanocytes to keratinocytes by lectins and neoglycoproteins in an in vitro model system. Pigment Cell Res 2001;14: 185194.
  • 100
    Sharlow ER, Paine C, Babiarz L, Eisinger M, Shapiro SS, Seiberg M. The protease activated receptor2 upregulates keratinocyte phagocytosis. J Cell Sci 2000;113: 30933101.
  • 101
    Seiberg M, Paine C, Sharlow E, Costanzo M, Andrade-Gordon P, Eisinger M, Shapiro S. The proteasome-activated receptor 2 regulates pigmentation via keratinocyte–melanocyte interaction. Exp Cell Res 2000;254: 2532.
  • 102
    Seiberg M, Paine C, Sharlow E, Costanzo M, Andrade-Gordon P, Eisinger M, Shapiro SS. Inhibition of melanosome transfer results in skin lightening. J Invest Dermatol 2000;115: 162167.
  • 103
    Paine C, Sharlow E, Liebel F, Eisinger M, Shapiro S, Seiberg M. An alternative approach to depigmentation by soybean extracts via inhibition of the PAR-2 pathway. J Invest Dermato 2001;116: 587595.
  • 104
    Hakozaki T, Minwalla L, Zhuang J, Chhoa M, Matsubara A, Miayamoto K, Greatens A, Hillebrand GG, Bissett DL, Boissy RE. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol 2002;147: 2031.
  • 105
    Smith W. The effects of topical L (+) lactic acid and ascorbic acid on skin withening. Int J Cosmetic Sci 1999;21: 3340.
  • 106
    Jahaveri SM, Handa S, Kaur I, Kumar B. Safety and efficacy of glycolic acid facial peel in Indian women with melasma. Int J Dermatol 2001;40: 354357.
  • 107
    Amer M, Metwalli M. Topical liquiritin improves melasma. Int J Dermatol 2000;39: 299301.
  • 108
    Imokawa G, Kobayashi T, Miyagishi M, Higashi K, Yada Y. The role of endothelin-1 in epidermal hyperpigmentation and signalling mechanisms of mitogenesis and melanogenesis. Pigment Cell Res 1997;10: 218228.
  • 109
    Hachiya A, Kobayashi T, Takema Y, Imokawa G. Biochemical characterization of endothelin-converting enzyme-1α in cultured skin-derived cells and its postulated role in the stimulation of melanogenesis in human epidermis. J Biol Chem 2002;277: 53955403.
  • 110
    Kligman AM, Willis I. A new formula for depigmenting human skin. Arch Dermatol 1975;111: 4048.
  • 111
    Westerhof W, Njoo MD. In: Katsambas AD, Lotti TM. European Handbook of Dermatological Treatments. Berlin: Springer; 1995. pp. 217223.
  • 112
    Katsambas A, Antoniou C, Melasma. Classification and treatment. J Eur Acad Dermatol 1995;4: 217223.
  • 113
    Yokota T, Nishio H, Kubota Y, Mizoguchi M. The inhibitory effect of glabridin from liquorice extracts on melanogenesis and inflammation. Pigment Cell Res 1998;11: 355361.
  • 114
    Stratigos AJ, Dover JS, Arndt KD. Laser treatment of pigmented lesions-2000. Arch Dermatol 2000;136: 915921.
  • 115
    Anderson RR. Laser in dermatology-a critical update. J Dermatol 2000;27: 700705.
  • 116
    Li YT, Yang KC. Comparison of the frequency-doubled Q-switched Nd:YAG laser and 35% trichloroacetic acid for the treatment of face lentigines. Dermatol Surg 1999;25: 202204.
  • 117
    Kunachak S, Leelaudomlipi P, Wongwaisayawan S. Dermabrasion: a curative treatment for melasma. Aesthetic Plast Surg 2001;25: 114117.
  • 118
    Goldman L, Rockwell RJ, Meyer R, Otten R, Wilson RG, Kitzmiller KW. Laser treatment of tatoos: a preliminary survey of three years' clinical experience. JAMA 1967;201: 841844.
  • 119
    Anderson RR, Parish JA. Selective photothermolysis. precise microsurgery by selective absorption of pulsed radiation. Science 1983;220: 524527.
  • 120
    Brazzini B, Hautmann G, Ghersetich I, Hercogova J, Lotti T. Laer tissue interaction in epidermal pigmented lesions. J Eur Acad Dermatol Venereol 2001;15: 388391.
  • 121
    Taylor CR, Anderson RR. Ineffective treatment of refractory melasma and post-inflammatory hyperpigmentation by Q-switched ruby laser. J Dermatol Surg Oncol 1994;20: 592597.
  • 122
    Nouri K, Bowes L, Charter T, Romagnosa R, Spencer J. Combination treatment of melasma with pulsed CO2 laser followed by Q-switched alexandrite laser: a pilot study. Dermatol Surg 1999;25: 494497.
  • 123
    Taylor CR, Anderson RR. Ineffective treatment of refractory melasma and post-inflammatory hyperpigmentation by swithched ruby laser. J Dermatol Surg Oncol 1994;20: 592597.
  • 124
    Virador VM, Kobayashi N, Matsunaga J, Hearing VJ. A standardized protocol for assessing regulators of pigmentation. Anal Biochem 1999;270: 207219.
  • 125
    Lei TC, Virador VM, Vieira WD, Hearing VJ. A melanocyte-keratinocyte coculture model to assess regulators of pigmentation in vitro. Anal Biochem 2002;305: 260268.
  • 126
    Hermanns JF, Petit L, Pierard-Franchimont C, Paquet P, Pierard GE. Assessment of topical hypopigmenting agents on solar lentigines of Asian wome. Dermatology 2002;204: 281286.